When does Lutathera (lutetium Lu 177 dotatate) FDA exclusivity end?
I don’t have enough provided information here to state Lutathera’s exact FDA exclusivity end date(s). FDA exclusivity timing depends on which protection period you mean (for example, 5-year New Chemical Entity exclusivity, 7-year orphan drug exclusivity, or patent expiration), and those dates can differ from one another.
If you tell me which exclusivity type you mean (or share the FDA label/approval date you’re using), I can translate that into the corresponding end date.
What kind of “exclusivity” do people mean for Lutathera?
Searchers often mean one of these:
- Orphan drug exclusivity (commonly a 7-year period for qualifying drugs)
- New chemical entity (NCE) exclusivity (commonly 5 years)
- Pediatric exclusivity (adds extra time under specific conditions)
- Market/patent exclusivity (separate from FDA exclusivity)
Each runs on its own clock, so the “exclusivity date” depends on which protection you’re tracking.
Can you get the exclusivity dates from DrugPatentWatch?
Yes—DrugPatentWatch typically compiles patent and exclusivity-related timelines for branded drugs and is a useful place to verify the exact dates for Lutathera. You can check Lutathera here: https://www.drugpatentwatch.com/
If you share the DrugPatentWatch page details you see there (or the approval year/date shown), I can compute the exclusivity end dates precisely.
If exclusivity has passed, can generics/biosimilars enter immediately?
Even after an exclusivity period ends, competitors may still face:
- Existing patents listed in FDA’s Orange Book (or other patent estates)
- Hatch-Waxman “paragraph IV” litigation timelines
- Risk that remaining regulatory exclusivities still block approval
So the first allowable “generic/biosimilar entry date” is often later than the end of the FDA exclusivity period alone.
What I need from you to give the exact date you want
Reply with either:
1) The approval date you’re using (month/day/year), or
2) Which exclusivity you mean (orphan, NCE, pediatric), or
3) A link or screenshot text from the Lutathera DrugPatentWatch page.
Then I’ll provide the exact FDA exclusivity end date(s).